Imugene: Cancer drug trial green lit by US FDA 

Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N’ Bears Report about Imugene’s “immunotherapy” drug that can laser-target cancerous cells in partnership with an already approved drug, potentially setting up a sublime pairing of products in the vanguard of the fight against cancer.

Imugene: Cancer drug trial green lit by US FDA 
Listen to ASX-listed Imugene Managing Director Leslie Chong talk to Matt Birney on the Bulls N’ Bears Report about Imugene’s “immunotherapy” drug that can laser-target cancerous cells in partnership with an already approved drug, potentially setting up a sublime pairing of products in the vanguard of the fight against cancer.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N’ Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia’s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N&rsquo; Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia&rsquo;s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Advertisement